following a full submission under the orphan equivalent medicine process:
enzalutamide (Xtandi®) is accepted for use within NHSScotland.
Indication under review: treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
Enzalutamide improved radiographic progression-free survival compared with placebo and it improved overall survival compared with placebo and an older non-steroidal anti-androgen (NSAA) in adults with mHSPC who were receiving ADT.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- enzalutamide (Xtandi)
- SMC ID:
For treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 07 February 2022